ETFMG Treatments Testing... Share Price

-0.0102 (-0.04%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 1,106
Bid Price
Ask Price
News -
Day High 23.2751


52 Week Range


Day Low 23.13
Company Name Etf Ticker Symbol Market Type
ETFMG Treatments Testing and Advancements ETF GERM AMEX Exchange Traded Fund
  Price Change Change Percent Etf Price Last Traded
-0.0102 -0.04% 23.2698 15:00:26
Open Price Low Price High Price Close Price Prev Close
23.13 23.13 23.2751 23.2698 23.28
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
30 1,106  23.25  25,714 - 20.185 - 40.53
Last Trade Time Type Quantity Etf Price Currency
17:00:00 100  23.2698 USD


Draw Mode:

ETFMG Treatments Testing and Advancements ETF Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 24.43M 1.05M 1.05M  -  - - 6.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
-  - 0.64% 09/21/22 - -

more financials information »

News ETFMG Treatments Testing...

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

GERM Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week24.2924.2923.1323.362,023-1.02-4.2%
1 Month21.9624.8921.9623.311,8081.315.96%
3 Months23.7524.8920.18521.962,120-0.4802-2.02%
6 Months22.8327.5520.18523.432,8610.43981.93%
1 Year37.9140.5320.18529.205,705-14.64-38.62%
3 Years25.3046.0620.18532.5328,177-2.03-8.02%
5 Years25.3046.0620.18532.5328,177-2.03-8.02%

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the Prime Treatments, Testing and Advancements Index. The index tracks the performance of U.S.-listed equity securities or depositary receipts of companies that (i) perform research, development, and commercialization of treatments or vaccines for infectious diseases or (ii) engage in the research, development, manufacturing, and provision of biological tests for patients. The fund invests at least 80% of its total assets in the component securities of the index. The fund is non-diversified.